David C Tully

USPTO Granted Patents = 27 (Patent Applications = 14)

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 5.0

ph-index = 4

Forward Citations = 44(Granted Patents)

Location History:

Middletown, NJ (US) (1999)
San Diego, CA (US) (2005 - 2013)
Danville, CA (US) (2017 - 2021)
Emeryville, CA (US) (2015 - 2023)

Company Filing History:

Gilead Sciences, Inc.

patents

4. 1 out of 832,680

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2025

where 'Filed Patents' based on already Granted Patents

27 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12338220 - Antiviral pyrazolopiridinone compounds (2025-06-24),

2. 11667613 - Antiviral pyrazolopyridinone compounds (2023-06-06),

3. 11072610 - Antiviral pyridopyrazinedione compounds (2021-07-27),

4. 11021446 - Compositions and methods for modulating farnesoid X receptors (2021-06-01),

5. 10683271 - Compositions and methods for modulating farnesoid X receptors (2020-06-16),

6. 10351576 - Fused tricyclic pyrazole derivatives useful for farnesoid X receptors (2019-07-16),

7. 10077240 - Compositions and methods for modulating farnesoid X receptors (2018-09-18),

8. 9963454 - Compounds and compositions for the treatment of parasitic disease (2018-05-08),

9. 9682939 - Compositions and methods for modulating farnesoid X receptors (2017-06-20),

10. 9469645 - Compounds and compositions for the treatment of parasitic diseases (2016-10-18),

11. 9150568 - Compositions and methods for modulating FXR (2015-10-06),

12. 8557801 - Compounds and compositions useful for the treatment of parasitic diseases (2013-10-15),

13. 8338469 - Compounds and compositions as channel activating protease inhibitors (2012-12-25),

14. 8293915 - Compounds and compositions as channel activating protease inhibitors (2012-10-23),

15. 8268996 - Compounds and compositions as cathepsin S inhibitors (2012-09-18),

Title: Spotlight on Inventor David C. Tully: Revolutionizing Antiviral Treatments

Introduction: David C. Tully, a brilliant innovator based in San Diego, CA, is making waves in the field of pharmaceuticals with his groundbreaking inventions. With an impressive 25 patents to his name, Tully is a trailblazer in developing antiviral treatments that have the potential to transform healthcare as we know it.

Latest Patents: Among Tully's latest patents are the Antiviral Pyrazolopyridinone Compounds and the Antiviral Pyridopyrazinedione Compounds. These inventions introduce compounds with Formula (I) that show promise in treating viral infections, particularly those caused by herpesviruses. The formulations, along with their pharmaceutical compositions, offer new avenues for combating infectious diseases and improving patient outcomes.

Career Highlights: Tully's journey in the pharmaceutical industry has seen him contribute significantly to companies such as Irm LLC and Novartis AG. His expertise and dedication have led to the development of innovative solutions that address critical medical needs, setting new standards for antiviral research and treatment.

Collaborations: Throughout his career, Tully has collaborated with esteemed professionals in the field, including coworkers Arnab Kumar Chatterjee and Hong Liu. Together, they have synergized their talents and knowledge to drive forward cutting-edge research and development initiatives, fostering a culture of innovation and excellence.

Conclusion: In conclusion, David C. Tully stands out as a visionary inventor who continues to push the boundaries of pharmaceutical innovation. With a rich portfolio of patents and a commitment to advancing antiviral treatments, Tully's work exemplifies the transformative power of ingenuity and perseverance in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.